Insider Transactions in Q2 2021 at Cyteir Therapeutics, Inc. (CYT)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2021
|
Jean George Director |
BUY
Conversion of derivative security
|
Indirect |
2,444,268
+50.0%
|
-
|
|
Jun 22
2021
|
Janwillem Naesens Director |
BUY
Open market or private purchase
|
Indirect |
277,777
+7.28%
|
$4,999,986
$18.0 P/Share
|
|
Jun 22
2021
|
Janwillem Naesens Director |
BUY
Conversion of derivative security
|
Indirect |
3,259,026
+50.0%
|
-
|
|
Jun 22
2021
|
Timothy Romberger Director |
BUY
Conversion of derivative security
|
Direct |
79,060
+17.63%
|
-
|
|
Jun 22
2021
|
Joseph S Zakrzewski Director |
BUY
Conversion of derivative security
|
Indirect |
58,671
+50.0%
|
-
|
|
Jun 22
2021
|
Invest Ii Sc Sp Droia > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
277,777
+7.28%
|
$4,999,986
$18.0 P/Share
|
|
Jun 22
2021
|
Invest Ii Sc Sp Droia > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,259,026
+50.0%
|
-
|
|
Jun 22
2021
|
Venrock Associates Vii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,259,025
+50.0%
|
-
|
|
Jun 22
2021
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
277,777
+5.43%
|
$4,999,986
$18.0 P/Share
|
|
Jun 22
2021
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,562,636
+50.0%
|
-
|